BioCryst Pharmaceuticals, Inc. (BCRX)
7.68
+0.03
(+0.39%)
USD |
NASDAQ |
Nov 12, 16:00
7.65
-0.03
(-0.39%)
After-Hours: 20:00
BioCryst Pharmaceuticals Shareholders Equity (Quarterly) : -397.38M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -397.38M |
| June 30, 2026 | -454.29M |
| March 31, 2026 | -553.84M |
| December 31, 2025 | -119.15M |
| September 30, 2025 | -387.89M |
| June 30, 2025 | -421.59M |
| March 31, 2025 | -451.93M |
| December 31, 2024 | -475.93M |
| September 30, 2024 | -468.56M |
| June 30, 2024 | -475.61M |
| March 31, 2024 | -476.17M |
| December 31, 2023 | -455.53M |
| September 30, 2023 | -410.99M |
| June 30, 2023 | -388.71M |
| March 31, 2023 | -328.29M |
| December 31, 2022 | -294.60M |
| September 30, 2022 | -242.66M |
| June 30, 2022 | -213.23M |
| March 31, 2022 | -164.22M |
| December 31, 2021 | -106.99M |
| September 30, 2021 | -147.04M |
| June 30, 2021 | -106.08M |
| March 31, 2021 | -74.99M |
| December 31, 2020 | -19.26M |
| September 30, 2020 | 33.64M |
| Date | Value |
|---|---|
| June 30, 2020 | 76.51M |
| March 31, 2020 | 3.648M |
| December 31, 2019 | 38.25M |
| September 30, 2019 | -41.25M |
| June 30, 2019 | -9.193M |
| March 31, 2019 | 22.51M |
| December 31, 2018 | 49.24M |
| September 30, 2018 | 72.87M |
| June 30, 2018 | 46.18M |
| March 31, 2018 | 62.05M |
| December 31, 2017 | 83.77M |
| September 30, 2017 | 100.63M |
| June 30, 2017 | 24.08M |
| March 31, 2017 | 38.53M |
| December 31, 2016 | 1.578M |
| September 30, 2016 | 3.993M |
| June 30, 2016 | 13.39M |
| March 31, 2016 | 27.80M |
| December 31, 2015 | 47.72M |
| September 30, 2015 | 64.04M |
| June 30, 2015 | 76.09M |
| March 31, 2015 | 64.37M |
| December 31, 2014 | 75.64M |
| September 30, 2014 | 83.45M |
| June 30, 2014 | 90.09M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Amgen, Inc. | 14.35B |
| Halozyme Therapeutics, Inc. | -55.24M |
| Neurocrine Biosciences, Inc. | 3.879B |
| Agenus, Inc. | -105.37M |
| Anika Therapeutics, Inc. | 137.58M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 591.07M |
| Total Liabilities (Quarterly) | 988.45M |
| Debt to Equity Ratio | -2.084 |
| Current Ratio | 2.712 |
| Net Debt Paydown Yield | -0.84% |